An interventional study of Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement in Congenital Heart Defect, Pulmonary Valve; Insufficiency, Congenital and Pulmonary Valve Stenosis, sponsored by Taewoong Medical Co., Ltd.. Completed at 5 sites in South Korea. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Heart Defects, Congenital with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Heart Defects, Congenital · Korea, Republic of.
Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, this one is one of 2 that started in 2017, is one of 8 with no phase, and was the 8th registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →2 of the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Pusan National University Yangsan Hospital · Sites in Korea, Republic of
Ages up to 2
Seoul National University Hospital · Sites in Korea, Republic of
Ages 8–18
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 36 across the 9 interventional studies, 310 across the 8 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 17 have an industry lead sponsor. The 7 most frequent:
This study is registered under Taewoong Medical Co., Ltd., one of the names counted as Olympus Corporation. Under that name alone:
Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Olympus Corporation has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
1 of the studies in Heart Defects, Congenital with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06041685Pusan National University Yangsan HospitalEffect of Local Warming for Arterial Catheterization in Pediatric Anesthesia | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Heart Defects, Congenital with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of the TPV in patients with pulmonary valve dysfunction.
The TPV is indicated for use in patients with previous undergone replacement of bioprosthetic valve or conduit due to either pulmonary valve atresia, stenosis, regurgitation or a combination of them and present with dysfunctional right ventricular ourflow tract (RVOT) requiring treatment for severe pulmonary regurgitation and/or RVOT conduit obstruction. Consecutive subject data should be collected at discharge, 1, 3, 6 month, and 1-5 years post TPV implantation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)
Device: Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement
Pulsta® Transcatheter Pulmonary Valve Replacement
Hemodynamic functional improvement at 6month
Hemodynamic functional improvement is defined as mean RVOT gradient ≤30 mmHg by continuous wave doppler, and a pulmonary regurgitant fraction \<20% by cardiac magnetic resonance (MR).
Time frame: 6 months
Procedural / Device related serious adverse events at 6month
Time frame: 6 months
Procedural success
Procedural success is defined as the TPV implant within desired position, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient \<35mmHg by catheter, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours post-implant.
Time frame: 5 days
Hemodynamic function
Hemodynamic function will be measured including peak RVOT pressure gradient, mean RVOT pressure gradient, RV-PA pressure gradient, RV pressure, cardiac output, cardiac index, RV end-diastolic volume by echocardiography, cardiac MR, or catheterization.
Time frame: 5 years
Severity of pulmonary regurgitation
Time frame: 5 years
New York Heart Association (NYHA) functional classification
Time frame: 5 years
Stent fracture
Stent fracture will be assessed by the investigator through radiography (X-ray, Fluoroscopy).
Time frame: 5 years
Catheter reintervention on TPV
Time frame: 5 years
Reoperation
Time frame: 5 years
Procedural / Device related serious adverse events
Time frame: 5 years
Death (all cause / procedural / device-related)
Time frame: 5 years
Other adverse events
Time frame: 5 years
Pulmonary regurgitant fraction
Pulmonary regurgitant fraction will be measured by cardiac MRI.
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2017 to primary completion in Nov 2019, 31 months.
Of 226 interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 57. This study's 31 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.